Allakos Inc

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chronic spontaneous urticaria (CSU) has been dosed in a randomized, double-blind, placebo-controlled Phase 1 trial of AK006.

Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

Allakos (NASDAQ: ALLK ) just reported results for the first quarter of 2024. Allakos reported earnings per share of -50 cents.

ALLK Stock Earnings: Allakos Meets EPS for Q1 2024

SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2024.

Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

Rapt Therapeutics Inc

Tonix Pharmaceuticals Hld

It is not a bad idea to hunt for biotech stocks to sell. Such stocks have earned a bad reputation among investors, and for good reason.

3 Biotech Stocks to Dump Before They Go to Zero

Allakos (ALLK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Allakos (ALLK): Strong Industry, Solid Earnings Estimate Revisions

SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

– Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages –

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

LOS ANGELES, CA / ACCESSWIRE / February 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

–  Data provide insights on the signaling pathways involved with AK006 mast cell inhibition –– AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells –

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

NEW YORK , Feb. 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allakos, Inc. ("Allakos" or the "Company") (NASDAQ: ALLK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLK

LOS ANGELES, CA / ACCESSWIRE / February 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

The heavy selling pressure might have exhausted for Allakos Inc. (ALLK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Here's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeks

Allakos (ALLK) decides to stop developing its lead drug after top-line data from two mid-stage studies did not achieve their primary endpoints.

Allakos (ALLK) Plummets 60% on Ending Development of Lead Drug

Allakos (NASDAQ: ALLK ) stock is taking a beating on Tuesday after the clinical stage biopharmaceutical company revealed results from its latest study. The bad news here comes from the company's Phase 2 and Phase 2b clinical trials of lirentelimab.

Why Is Allakos (ALLK) Stock Down 57% Today?

Here is how Allakos Inc. (ALLK) and McKesson (MCK) have performed compared to their sector so far this year.

Is Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?

Allakos Inc said on Tuesday that it plans to discontinue the development of its experimental skin disease drug after it failed two mid-stage studies.

Allakos to stop further development of skin disease drug, plans job cuts

SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced a restructuring to reduce costs and to focus on AK006 clinical development and additional preclinical programs. As a result, the Company's cash runway is expected to extend into mid-2026.

Allakos Announces a Restructuring to Focus on Development of AK006

SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2023.

Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results

An analyst's recommendation may have helped boost Allakos stock. Allakos has two lead therapies to treat autoimmune skin disorders.

Why Shares of Allakos Are Up Wednesday

Allakos displays fiscal discipline with YoY reductions in R&D and G&A, suggesting resource reallocation to pivotal assets like lirentelimab. Lirentelimab's Phase 2a data is promising, particularly for omalizumab-refractory patients, but late-phase results are keys to the drug's validation. Investment Recommendation: Speculative "Buy" advised for bold investors. Initiate starter positions, closely monitor upcoming Phase 2b data and cash burn rate.

News for Allakos Inc Stock (ALLK)